Preliminary 2021 STD Surveillance Data

2.5 million

Preliminary data show 2.5 million reported cases of chlamydia, gonorrhea, and syphilis in 2021.

STDs continued to increase during the second year of the COVID-19 pandemic, with no signs of slowing. This page presents preliminary STD surveillance data for chlamydia, gonorrhea, syphilis, and congenital syphilis. These data include cases reported to CDC through the National Notifiable Diseases Surveillance System (as of July 7, 2022), STD Surveillance Network (as of June 15, 2022), and Gonococcal Isolate Surveillance Project (as of June 23, 2022), and are considered preliminary as 2021 STD surveillance data will continue to be reported to CDC through the fall of 2022. Final 2021 data, including STD case counts and rates for states and territories, will be provided in the forthcoming 2021 STD Surveillance Report. Until then, the most current complete data for chlamydia, gonorrhea, and syphilis are available in Sexually Transmitted Disease Surveillance, 2020.

Chlamydia Cases - 4.7% decrease
Gonorrhea Cases
Syphilis Cases
Congenital Syphilis Cases

Featured Slides

Slide 4Slide 13Slide 21Slide 22Slide 29Slide 34Slide 38Slide 41

PDF version

Table 24. Trends in Reported Cases and Rates of Reported Cases for Nationally Notifiable STDs, United States, 2017-2021*
Disease Sex**
Cases
Percent Change
2017 2018 2019 2020 2021* 5 Year 1 Year
Chlamydia Men 577,644 610,447 644,337 548,676 578,170 0.1 5.4
Women 1,127,651 1,145,063 1,160,470 1,027,061 1,035,221 -8.2 0.8
Total 1,708,569 1,758,668 1,808,703 1,579,885 1,628,397 -4.7 3.1
Gonorrhea Men 322,169 341,401 361,586 385,551 401,435 24.6 4.1
Women 232,587 241,074 253,359 290,666 289,905 24.6 -0.3
Total 555,608 583,405 616,392 677,769 696,764 25.4 2.8
Total Syphilis Total 101,590 115,062 129,818 133,955 171,074 68.4 27.7
   Congenital Syphilis† Total 941 1,323 1,875 2,158 2,677 184.5 24.1
   Primary and Secondary Syphilis Men 26,885 30,034 32,402 33,646 40,145 49.3 19.3
Women 3,722 4,995 6,493 7,901 11,772 216.3 49.0
Total 30,644 35,063 38,992 41,655 52,354 70.8 25.7
   Early Non-Primary Non-Secondary Syphilis Men 29,251 32,619 34,427 35,165 39,941 36.5 13.6
Women 4,684 5,891 7,081 7,809 10,229 118.4 31.0
Total 34,013 38,539 41,655 43,145 50,592 48.7 17.3
   Unknown Duration or Late Syphilis‡ Men 26,178 28,872 32,411 31,868 42,710 63.2 34.0
Women 9,740 11,232 14,598 14,959 22,461 130.6 50.2
Total 35,992 40,137 47,296 46,997 65,451 81.8 39.3
Combined Total of Chlamydia, Gonorrhea, and Total Syphilis Total 2,365,767 2,457,135 2,554,913 2,391,609 2,496,235 5.5 4.4

 

Table 24. Trends in Reported Cases and Rates of Reported Cases for Nationally Notifiable STDs, United States, 2017-2021*
Disease Sex**
Rates per 100,000 Population
Percent Change
2017 2018 2019 2020 2021* 5 Year 1 Year
Chlamydia Men 360.1 378.9 398.6 334.2 351.7 -2.3 5.2
Women 682.1 689.6 696.6 614.1 618.0 -9.4 0.6
Total 524.6 537.5 551.0 476.7 490.6 -6.5 2.9
Gonorrhea Men 200.8 211.9 223.7 234.8 244.2 21.6 4.0
Women 140.7 145.2 152.1 173.8 173.1 23.0 -0.4
Total 170.6 178.3 187.8 204.5 209.9 23.0 2.6
Total Syphilis Total 31.2 35.2 39.5 40.4 51.5 65.1 27.5
   Congenital Syphilis† Total 24.4 34.9 50.0 59.7 74.1 203.7 24.1
   Primary and Secondary Syphilis Men 16.8 18.6 20.0 20.5 24.4 45.2 19.0
Women 2.3 3.0 3.9 4.7 7.0 204.3 48.9
Total 9.4 10.7 11.9 12.6 15.8 68.1 25.4
   Early Non-Primary Non-Secondary Syphilis Men 18.2 20.2 21.3 21.4 24.3 33.5 13.6
Women 2.8 3.5 4.3 4.7 6.1 117.9 29.8
Total 10.4 11.8 12.7 13.0 15.2 46.2 16.9
   Unknown Duration or Late Syphilis‡ Men 16.3 17.9 20.0 19.4 26.0 59.5 34.0
Women 5.9 6.8 8.8 8.9 13.4 127.1 50.6
Total 11.1 12.3 14.4 14.2 19.7 77.5 38.7
Combined Total of Chlamydia, Gonorrhea, and Total Syphilis Total 726.3 751.0 778.4 721.6 752.1 3.6 4.2
* Reported 2021 data are preliminary as of July 7, 2022.
** Total includes cases reported with unknown sex.
† Sex of infant is not reported. Rates are per 100,000 live births.
‡ The case classification of ‘Unknown duration or late syphilis’ went into effect in January 2018. During 2017, cases in this category include cases classified as late latent syphilis and late syphilis with clinical manifestations. See 2020 Technical Notes for a detailed explanation of changes to the syphilis case definition.
NOTE: The COVID-19 pandemic has introduced uncertainty and difficulty in interpreting case data. See Impact of COVID-19 on STDs for more information.

Suggested Citation

All material contained in this report is in the public domain and may be used and reprinted without special permission; however, citation as to source is appreciated.

Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance: Preliminary 2021 Data. Atlanta: US Department of Health and Human Services; 2022.

 

Sexually Transmitted Disease Surveillance: Preliminary 2021 Data presents trends in nationally notifiable sexually transmitted diseases (STDs) in the United States based on preliminary 2021 data and intended as a reference document for policy makers, program managers, health planners, researchers, and others who are concerned with the public health implications of these diseases.

As the COVID-19 pandemic continues to cause reporting delays, the preliminary 2021 data reflect data provided to CDC through the National Notifiable Diseases Surveillance System (NNDSS) as of July 7, 2022, through the STD Surveillance Network (SSuN) as of June 15, 2022, and through the Gonococcal Isolate Surveillance Project (GISP) as of June 23, 2022. These data are considered preliminary as STD surveillance data collected during 2021 will continue to be provided to CDC through fall of 2022. Final 2021 data, including STD case counts and rates for states and territories, will be included in the 2021 STD Surveillance Report when it is released in 2023.

During 2021, the COVID-19 pandemic continued to impact trends in diagnosed and reported STDs, as well as in data collected through enhanced and sentinel STD surveillance activities; therefore, the STD data presented in this report for the years 2020 and 2021 should be interpreted with caution. For more information, see Impact of COVID-19 on STDs.

The data and methodology used in this preliminary report are similar to those used for the 2020 STD Surveillance Report. See the STD Surveillance Report 2020: Technical Notes for a full description of data sources and methodology.  

The following details are specific for the the 2021 preliminary STD case data collected through NNDSS:

  • NNDSS STD case notification data presented in this report are compiled from electronic data received through the National Electronic Telecommunications System for Surveillance (NETSS) and via Health level 7 (HL7) messaging using National Electronic Disease Surveillance System (NEDSS) standards. Additionally, select jurisdictions provide congenital syphilis cases via REDCap. In 2021, nine jurisdictions (Alabama, Connecticut, Idaho, Kentucky, Michigan, North Carolina, Oregon, South Carolina, and Wisconsin) provided STD case notification data to CDC via HL7 messaging. In 2021, 34 states provided congenital syphilis data through REDCap.
  • Denominators for rates of reported cases of STDs, excluding congenital syphilis, use population estimates from the United States Census Bureau. For figures presenting race using the 1997 Office of Management and Budget standards, non-bridged-race data are used. The most recently available population estimates at time of publication are used, with case rates for 2021 calculated using 2021 population estimates. Because of the use of the updated population data, case rates for 2000–2020 may be different from those presented in previous STD surveillance reports.
  • Congenital syphilis rates were calculated by using live birth data provided to National Center for Health Statistics through the Vital Statistics Cooperative Program. The most recently available data at time of publication are used, with case rates for 2020 and 2021 calculated using 2020 live birth data. Because of the use of the updated population data, case rates for 2000–2020 may be different from those presented in previous STD surveillance reports.